Pfizer Corporation

Thomas Francis Seeger

Gene M Bright

Kishor A Desai

Christopher Joseph Schmidt

Harry Ralph Howard

Harry R Howard, Jr

Mark Leonard Elliott

Mark Leonard Elliot

Teresa A Smolarek

The present invention relates to compounds that are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.

Monoamine reuptake inhibitors for treatment of CNS disorders

Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines

Antipsychotic compounds having the formula ##STR1## wherein Z is H or Cl; Y is O or S; n is 1-4; separately, X is H or (C.sub.1 -C.sub.2)alkyl and L is R(CH.sub.2).sub.m CO, m is 0 or 1-3, R is (C.sub.1 -C.sub.6)alkyl, (C.sub.3 -C.sub.7)cycloalkyl, phenyl, naphthyl, furyl, benzofuranyl, thienyl, benzothienyl, pyrrolyl, indolyl, isoindolyl or one of said groups substituted on aromatic or heteroaromatic ring with fluoro, chloro, (C.sub.1 -C.sub.2)alkyl or (C.sub.1 -C.sub.2)alkoxy; or together L and X, in combination with the nitrogen to which they are attached, form certain cyclic imides, 4-substituted piperidines or a cyclic sulfonamide.

Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines

Growing community of inventors

Mystic, CT, United States of America

Thomas Francis Seeger